Lundbeck still looking for acquisitions despite positive Alzheimer's data
![Lundbeck CEO Deborah Dunsire | Photo: Gregers Tycho/ERH](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13535793.ece/ALTERNATES/schema-16_9/doc7iqhwrce41sgnccumks.jpg)
Lundbeck is still interested in acquisitions, despite the fact that the firm and its partner Otsuka Pharmaceuticals released positive phase III data for its candidate brexpiprazol on Monday. The target indication is agitation in Alzheimer’s patients, which is often demonstrated through angry outbursts.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Lundbeck lawyer says pharma is fighting over legal talent
For subscribers